Forgot login?   Register

Medical Design Briefs

  Subscribe to Defense Tech Briefs  
  • Home
  • News
  • Features
  • Tech Briefs
  • Products
  • White Papers
  • Webinars
  • Video
  • Subscribe

Topics

  • Manufacturing & Prototyping
  • Surgical Robotics
  • Custom & Contract Manufacturing
  • Software
  • Imaging & Diagnostics
  • Monitoring & Testing
  • Rehabilitation & Physical Therapy
  • Biosensors
  • Drug Delivery & Dispensing
  • Electronics
  • Automation & Controls
  • Implants & Prosthetics
  • Mechanical Components
  • Materials / Adhesives / Coatings
  • Surgical Lasers
  • Optics/Photonics
  • Inspection Equipment

Newsletter

Subscribe today to receive the INSIDER, a FREE e-mail newsletter from Medical Design Briefs featuring exclusive previews of upcoming articles, late breaking NASA and industry news, hot products and design ideas, links to online resources, and much more.

Sign up now >>

Assessing a Patient's Risk for Sudden Cardiac Arrest

Posted in Patient Monitoring, Diagnostics, Features, MDB on Tuesday, May 01 2012

Page 2 of 2

According to American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines issued for the Management of Patients with Ventricular Arrhythmias and Prevention of Sudden Cardiac Death, it is reasonable to use MTWA testing to improve the diagnosis and risk stratification for those who are at risk of developing life-threatening ventricular arrhythmias (Class IIa, Level of Evidence: A).

MTWA testing is indicated for any patient at risk for lifethreatening ventricular tachyarrhythmias or sudden cardiac arrest, particularly those with heart failure, reduced ejection fraction (heart pumping capacity), prior heart attack, unexplained syncope (loss of consciousness or fainting), or family history of SCA.

Where it Stands

Cambridge Heart’s Analytic Spectral Method is the only Medicare-reimbursable technique for measuring MTWA. Cambridge Heart’s MTWA test is also reimbursed by a growing number of private payers including United Healthcare, Aetna, Cigna, Humana, Harvard Pilgrim Healthcare, and several BCBS plans.

In July 2010, Medicare updated its guidelines to allow MTWA to be performed during the same patient visit as a stress procedure (including stress echo and nuclear stress) with full reimbursement for each test. Lifting the previous restriction on same-day testing results in more convenience for patients and a more efficient testing schedule for physician practices.

Cambridge Heart’s HearTwave® II system is a third-generation product for measuring MTWA. The PC-based unit employs the Analytic Spectral Method to measure alternans at the level of 1 microvolt, so small that it is not detectable on a standard ECG. The HearTwave II can be used for standard stress testing as well as MTWA assessment.

Through a partnership with Cardiac Science, the market leader in stress testing equipment, MTWA is now available on the Q-Stress line of cardiac stress testing systems.

More Information
For more information about MTWA testing, visit http://info.hotims.com/40433-184.

blog comments powered by DISQUS back to top

«StartPrev12NextEnd»

MDB Digital Magazine


Click on thumbnail to view last month's issue.
Subscribe now to get access to the latest issue.

Outsourcing Guide

 

 

Subscribe to Medical Design Briefs

Trending this Month

© 2009-2013 Tech Briefs Media Group an SAE International Company

  • About
  • Contact
  • Advertising
  • Privacy
  • Subscribe

publications:

  • Defense Tech Briefs
  • Embedded Technology
  • NASA Tech Briefs
  • Green Design Briefs